Activated T cells modulate immunosuppression by embryonic-and bone marrow-derived mesenchymal stromal cells through a feedback mechanism

References

• Xu C, Jiang J, Sottile V, McWhir J, Lebkowski J, Carpenter MK. Immortalized fibroblast-like cells derived from human embryonic stem cells support undifferentiated cell growth. Stem Cells. 2004;22:972–80.
   PubMed Web of Science ®Google Scholar
• Barberi T, Willis LM, Socci ND, Studer L. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med. 2005;2:e161, 554–60.
   Google Scholar
• Olivier EN, Rybicki AC, Bouhassira EE. Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells. Stem Cells. 2006;24:1914–22.
   PubMed Web of Science ®Google Scholar
• Trivedi P, Hematti P. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol. 2008;36:350–9.
   PubMedGoogle Scholar
• Lian Q, Lye E, Suan Yeo K, Khia Way Tan E, Salto-Tellez M, Liu TM, . Derivation of clinically compliant MSCs from CD105 + , CD24– differentiated human ESCs. Stem Cells. 2007;25:425–36.
   PubMed Web of Science ®Google Scholar
• Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp Hematol. 2000;28:707–15.
   PubMed Web of Science ®Google Scholar
• Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004;22:675–82.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509–25.
   PubMed Web of Science ®Google Scholar
• Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, . Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011;17:534–41.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–22.
   PubMed Web of Science ®Google Scholar
• Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, . Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107:367–72.
   PubMed Web of Science ®Google Scholar
• Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM, . Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 2006;12:2263–73.
   PubMedGoogle Scholar
• Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, . T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12:47–57.
   PubMed Web of Science ®Google Scholar
• Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, . Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516–25.
   PubMed Web of Science ®Google Scholar
• Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia. 2005;19:1597–604.
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005; 305:33–41.
   PubMed Web of Science ®Google Scholar
• Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, . Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–98.
   PubMed Web of Science ®Google Scholar
• Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619–21.
   PubMed Web of Science ®Google Scholar
• Nasef A, Zhang YZ, Mazurier C, Bouchet S, Bensidhoum M, Francois S, . Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol. 2009;31:9–19.
   PubMed Web of Science ®Google Scholar
• Ren G, Su J, Zhang L, Zhao X, Ling W, L'Huillie A, . Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009;27: 1954–62.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, . Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3 + regulatory T cells. Stem Cells. 2008;26:212–22.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890–6.
   PubMed Web of Science ®Google Scholar
• Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology. 2002;107:452–60.
   PubMed Web of Science ®Google Scholar
• Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, . Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191–3.
   PubMed Web of Science ®Google Scholar
• Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196:459–68.
   PubMed Web of Science ®Google Scholar
• Zaher SS, Germain C, Fu H, Larkin DF, George AJ. 3-hydroxykynurenine suppresses CD4 + T cell proliferation, induces T regulatory cell development and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci. 2011 Apr 22;52(5):2640–8.
   PubMedGoogle Scholar
• Yen BL, Chang CJ, Liu KJ, Chen YC, Hu HI, Bai CH, . Brief report. Human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells. 2009;27:451–6.
   PubMedGoogle Scholar
• Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, . Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol. 2007;179:1595–604.
   PubMed Web of Science ®Google Scholar
• Jones S, Horwood N, Cope A, Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol. 2007;179:2824–31.
   Google Scholar
• Liu TM, Martina M, Hutmacher DW, Hui JH, Lee EH, Lim B. Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells. 2007;25:750–60.
   PubMed Web of Science ®Google Scholar
• Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC, . Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood. 2005;105:3824–32.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
   PubMed Web of Science ®Google Scholar
• Wada N, Bartold PM, Gronthos S. Human foreskin fibroblasts exert immunomodulatory properties by a different mechanism to bone marrow stromal/stem cells. Stem Cells Dev. 2011;20:647–59.
   PubMedGoogle Scholar
• Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006;6:613–25.
   PubMed Web of Science ®Google Scholar